Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
Journal Title:
Am Soc Clin Oncol Educ Book
Original Publication Date:
Jan 2017
Hypomethylating agents (HMAs) are the mainstay treatment of patients with
Bone Marrow Disease(s):